Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333448 | 0.75 | TSHR (0.34) | CYP19A1 | |
| SCHEMBL16322256 | 0.74 | CYP19A1 (0.33) | CYP19A1 | |
| SCHEMBL959235 | 0.74 | CYP19A1 (0.33) | CYP19A1 | |
| SCHEMBL16321921 | 0.73 | POLB (0.33) | CYP19A1 | |
| SCHEMBL10285357 | 0.70 | CA1 (0.36) | CYP19A1 | |
| SCHEMBL12697758 | 0.70 | CES2 (0.33) | CYP19A1 | |
| SCHEMBL16801016 | 0.69 | TAAR1 (0.36) | CYP19A1 | |
| SCHEMBL6432193 | 0.68 | POLB (0.36) | CYP19A1SMN1; SMN2 | |
| SCHEMBL16801035 | 0.67 | GRIN1 (0.41) | — | |
| SCHEMBL8996595 | 0.65 | SMN1; SMN2 (0.40) | CYP19A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0299727-B1 | THERAPEUTIC AGENTS | Pfizer Limited (GB) | 1991-11-13 | — | — | EP | claimed |
| EP-0299727-A1 | Therapeutic agents | Pfizer Limited (GB) | 1989-01-18 | — | — | EP | claimed |
| WO-2015083130-A1 | FUSED PYRIDINE AND PYRIMIDINE DERIVATIVES AS ROR GAMMA MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015083130-A1 | FUSED PYRIDINE AND PYRIMIDINE DERIVATIVES AS ROR GAMMA MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2015-06-11 | — | — | WO | disclosed |
| US-7598384-B2 | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-10-06 | — | — | US | disclosed |
| US-7598384-B2 | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-10-06 | — | — | US | disclosed |
| US-7598384-B2 | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-10-06 | — | — | US | disclosed |
| US-20090227582-A1 | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227582-A1 | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227582-A1 | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-09-10 | — | — | US | disclosed |
| US-7550482-B2 | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-06-23 | — | — | US | disclosed |
| US-6593335-B1 | Disease than can be ameliorated with a potassium channel opener in a host mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of claim 1; said disease is epilepsy, Raynaud's | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| EP-1278746-A2 | DIHYDROPYRIDINE COMPOUNDS AND METHODS OF USE | Abbott Laboratories (US) | 2003-01-29 | — | — | EP | disclosed |
| EP-1194429-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001083480-A2 | DIHYDROPYRIDINE COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2001-11-08 | — | — | WO | disclosed |
| WO-2000078768-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | disclosed |
| EP-0299727-B1 | THERAPEUTIC AGENTS | Pfizer Limited (GB) | 1991-11-13 | — | — | EP | disclosed |
| US-4992447-A | Asthma | PFIZER INC. (US) | 1991-02-12 | — | — | US | disclosed |
| US-4853392-A | Fused 1,4-dihydropyridines as antiallergy and antiinflammatory agents | PFIZER INC. (US) | 1989-08-01 | — | — | US | disclosed |
| EP-0299727-A1 | Therapeutic agents | Pfizer Limited (GB) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227582-A1 | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors | GRM1, GRM5, GRM2 | CYP19A1 4077/4885RAB9A 1065/4885SMN1; SMN2 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.